Department of Gastroenterology, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.
J Dig Dis. 2012 Apr;13(4):195-9. doi: 10.1111/j.1751-2980.2012.00579.x.
Inflammatory bowel disease (IBD) has been an international hot spot for research for a long period of time. In China, the prevalence of IBD is rapidly increasing in recent years, mimicking the same fast growing footsteps of the developed world. Chinese literature of the 20(th) century shows that the total number of IBD cases increased by approximately 2.5-fold over the previous decade, in particular a 15.7-fold in patients with Crohn's disease (CD). Articles on basic research have increased 4.3-fold, with a particular 9.9-fold increase on immunological mechanisms. The predominantly Traditional Chinese Medicine (TCM) related clinical trials implied tendency to use a combination of Western Medicine and TCM in the management of Chinese IBD patients. IBD research and collaborations overseas have been markedly promoted since the Chinese Organization for the Study of Inflammatory Bowel Disease (COIBD) was founded at the beginning of the 21(st) century. From the second decade of the century onwards, we need to focus on the research hot spots to catch up with the rapid advances worldwide. Big challenges and present achievements provide us with great opportunities for further developments of the study on IBD. The development of some novel target pathogenic factors of the disease will provide us with more effective roll for modern management and optimistic treatment of IBD during this century.
炎症性肠病（IBD）长期以来一直是国际研究热点。近年来，中国的 IBD 患病率迅速上升，与发达国家的快速增长步伐相吻合。中国 20 世纪的文献表明，IBD 病例总数在上一个十年增加了约 2.5 倍，特别是克罗恩病（CD）患者增加了 15.7 倍。基础研究文章增加了 4.3 倍，免疫机制方面尤其增加了 9.9 倍。以中医药为主的临床试验表明，中国 IBD 患者的治疗倾向于采用中西医结合的方法。自 21 世纪初中国炎症性肠病研究组织（COIBD）成立以来，海外的 IBD 研究和合作明显得到了推动。从本世纪第二个十年开始，我们需要关注研究热点，以赶上全球的快速发展。巨大的挑战和当前的成就为我们进一步开展 IBD 研究提供了很好的机会。一些疾病新的靶向致病因素的发展将为我们提供更有效的现代管理和乐观的治疗 IBD 提供帮助。
